...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.
【24h】

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.

机译:转导以表达MHC I类限制的表位特异性TCR的CD4 + CD25-T细胞在人黑素瘤模型中合成Th1细胞因子,并表现出MHC I类限制的溶细胞效应功能。

获取原文
获取原文并翻译 | 示例

摘要

Cytolytic T cell-centric active specific and adoptive immunotherapeutic approaches might benefit from the simultaneous engagement of CD4(+) T cells. Considering the difficulties in simultaneously engaging CD4(+) and CD8(+) T cells in tumor immunotherapy, especially in an Ag-specific manner, redirecting CD4(+) T cells to MHC class I-restricted epitopes through engineered expression of MHC class I-restricted epitope-specific TCRs in CD4(+) T cells has emerged as a strategic consideration. Such TCR-engineered CD4(+) T cells have been shown to be capable of synthesizing cytokines as well as lysing target cells. We have conducted a critical examination of functional characteristics of CD4(+) T cells engineered to express the alpha- and beta-chains of a high functional avidity TCR specific for the melanoma epitope, MART-1(27-35), as a prototypic human tumor Ag system. We found that unpolarized CD4(+)CD25(-) T cells engineered to express the MART-1(27-35) TCR selectively synthesize Th1 cytokines and exhibit apotent Ag-specific lytic granule exocytosis-mediated cytolytic effector function of comparable efficacy to that of CD8(+) CTL. Such TCR engineered CD4(+) T cells, therefore, might be useful in clinical immunotherapy.
机译:溶细胞性T细胞为中心的主动特异性和过继性免疫治疗方法可能会受益于CD4(+)T细胞的同时参与。考虑到在肿瘤免疫治疗中同时参与CD4(+)和CD8(+)T细胞的困难,特别是以Ag特异性方式,通过I类MHC的工程化表达将CD4(+)T细胞重定向至MHC I类限制的抗原决定簇限制CD4(+)T细胞中的表位特异性TCRs已成为一项战略考虑。此类TCR工程改造的CD4(+)T细胞已被证明能够合成细胞因子以及裂解靶细胞。我们已经对CD4(+)T细胞的功能特性进行了严格的检查,该CD4(+)T细胞被设计为表达针对黑色素瘤抗原决定簇MART-1(27-35)的高功能亲和力TCR的α-链和β-链,作为原型人类肿瘤Ag系统。我们发现工程设计以表达MART-1(27-35)TCR的非极化CD4(+)CD25(-)T细胞选择性地合成Th1细胞因子,并显示出与之相当的有效的Ag特异性裂解颗粒胞吐介导的细胞溶解效应子功能。 CD8(+)CTL。因此,此类TCR工程改造的CD4(+)T细胞可能在临床免疫治疗中有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号